WEBINARS

 

In these uncertain times, we’re offering our community a way to stay connected and share ideas. Every week, we’re creating a virtual space to come together and explore the most important topics in the industry right now.

Every webinar is free to attend via GoToWebinar.

PAST WEBINARS

 

What will be the impact of COVID-19 on Market Access and Pharma Companies?

16 April

We spoke to Fabrizio Gianfrate, Professor of Health Economics and Outcomes Research, University of Ferrara about:

  • The consequences of delaying projects and access to new therapies
  • Exploring the financial impact on pricing and reimbursement
  • The overall impact on market access methodology and how the technical nature will change

VIEW ON DEMAND

Fabrizio Gianfrate, Professor of Health Economics and Outcomes Research, University of Ferrara

Evolution or Revolution? Drug Evaluation in the US

22 April

Together with Edmund Pezalla, Former VP Pharmaceutical Policy and Strategy, Aetna we discussed:

  • What are the key factors motivating change in the US?
  • What is the role of Federal and State Government and Private Payers?
  • How can Pharma develop a meaningful response to these changes?

WATCH ON DEMAND

Edmund Pezalla, Former VP Pharmaceutical Policy and Strategy, Aetna

 

Patient Access & Affordability in the US and the Current Pandemic Landscape

28 April

Together with Elizabeth Johnson, LPN, CPC, Biologics Coordinator, Allergy Partners P.A. we discussed:

  • New affordability support
  • New programs launched due to COVID to cover costs associated with the virus
  • Suspension of authorizations and referrals
  • Planning for the new "normal" and keeping up with yearly demands

WATCH ON DEMAND

Elizabeth Johnson, LPN, CPC, Biologics Coordinator, Allergy Partners P.A.

The Health Economics of a Pandemic

Wednesday 06 May

Moderator:  Chris Pashos, Former Vice President, Global Evidence Strategy, AbbVie

Tune in as we speak to:

Alex Bastian, Vice President, Value & Market Access, Galapagos

Elizabeth Johnson, LPN, CPC, Biologics Coordinator, Allergy Partners P.A.

Topics on the agenda include:

  • The simulation of the medical advantage/benefit of covid-19 early tests
  • The analysis of the effects of your vaccination against covid-19 on the population
  • Evaluate the clinical and economic impact of successful treatment of covid-19 patients in intensive care units
  • Impact of Specialty Medications

WATCH ON DEMAND

 

Building evidence through collaboration: Working with patient organisations to prepare for access

Wednesday 13 May

This webinar is hosted by Josie Godfrey, Director, JG Zebra Consulting. We'll discuss:

  • Understanding opportunities for collaboration - when does working together to build evidence make sense?
  • What types of evidence can be created collaboratively?
  • Overcoming hurdles - lessons from Project HERCULES

WATCH ON DEMAND  

Josie Godfrey, Director, JG Zebra Consulting

 

Clinical Trials and Health Technology Assessment: Can we incorporate what patient’s value?

27 May

Moderated by: Fabrizio Gianfrate, Professor of Health Economics and Outcomes Research, University of Ferrara 

Panel discussion with:

Erin Mistry, SVP, Head of Payer Strategy, Gov't Affairs & Trade Relations, CorMedix

Edmund Pezalla, Former VP Pharmaceutical Policy and Strategy, Aetna

 

Topics on the agenda include:

  • What do patients value?
  • Strengthening the patient's voice and making sure they are heard properly
  • How the US can learn from other models?

WATCH ON DEMAND

 

Erin Mistry, Cormedix

Edmund Pezalla, Aetna

 

Why and how to build a successful global tender business?

03 June

We spoke to the Founder of Growpal, Nico Bacharidis about how to build a successful global tender business?

  • Topics on the agenda include:
  • Why is this critical for your company?
  • What are the main components of a successful tender business?
  • How to build it?

WATCH ON DEMAND  

  Founder of Growpal, Nico Bacharidis

The use of RWE and how it can bridge the gap between regulatory and payer needs

17th June

Moderated by: Daniel Jackson, Global Head Of Market Access, Solutions And Strategy, UCB

Panel discussion with:

Enkeleida Nikai-Fitzgerald, Head of Real World Evidence, Janssen

Rebecca Walker, Director, Global Access Strategy, UCB

Anna Scowcroft, Real World Evidence Lead Scientist, UCB

  • Looking at how regulators are accepting of surrogate endpoints for marketing authorisation in certain diseases
  • Understanding that Payer evidence requirements may be higher, with surrogate endpoints not highly valued
  • Complementary evidence such as real-world evidence (RWE) can be generated to optimise the value proposition at launch but its impact on HTA outcomes, price and access varies

 

Daniel Jackson, Global Head Of Market Access, Solutions And Strategy, UCB

 Enkeleida Nikai-Fitzgerald, Head of Real World Evidence, Janssen

Rebecca Walker, Director, Global Access Strategy, UCB

Anna Scowcroft, Real World Evidence Lead Scientist, UCB

 
 

Contact us

To sponsor or exhibit:
Edmond Rama
+44 (0)207 092 1052

edmond.rama@terrapinn.com

To speak:
Chris Shanks
+44 (0)207 092 1151

chris.shanks@terrapinn.com